Search
To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).
A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule.
Immunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.
Despite an effective vaccine, measles remains a major health problem globally, particularly in developing countries. More than 30% of children show primary...
A pooled analysis was conducted of 1,257 toddlers who received a fourth dose of Haemophilus influenzae type b- Neisseria meningitidis serogroups C and...
Measles virus causes severe morbidity and mortality, despite the availability of measles vaccines. Successful defence against viral pathogens requires early...
Despite the availability of measles vaccines, infants continue to die from measles. Measles vaccine responses vary between individuals, and poor...
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent...
We investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
The functionality and effects of TLR7 and TLR8 polymorphisms on cellular and antibody responses was investigated after the first measles vaccine dose.